Nous avons le plaisir de vous informer que notre organisation sera présente lors du congrès ESMO 2025, qui se tiendra à Berlin du 17 au 21 octobre 2025. Cet événement international majeur en oncologie sera l’occasion de partager nos avancées scientifiques et de mettre en valeur le travail de nos équipes.
Merci à toutes et tous pour votre engagement qui rend ces réalisations possibles.
Nous présenterons :
- Mini oral PRODIGE 81 - TRIPLET
Adding Ipilimumab (IPI) to Atezolizumab (ATEZO) plus Bevacizumab (BEV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in first-line systemic therapy (1L): PRODIGE 81/FFCD 2101 - TRIPLET HCC
P. Merle - Mini oral FFCD 1605 - OPTIPRIME
FOLFOX plus PANITUMUMAB (Pmab) according to a “stop-and-go” strategy in first-line in patients (pts) with non-mutated RAS/BRAF metastatic colorectal cancer (mCRC). Results of the FFCD 1605 – OPTIPRIME phase II trial.
JB. Bachet - Poster PRODIGE 85 - KANALRAD
Tolerance and Feasibility of Induction chemotherapy with mDCF prior to Chemoradiotherapy for Locally Advanced Squamous Cell Carcinomas of the Anal Canal: Planned safety Analysis of the PRODIGE 85-FFCD-KANALRAD trial
V. Vendrely - Poster PRODIGE 55 - SOCRATE
Ramucirumab (Ram) +/- Paclitaxel (Pacli) as second-line (L2) therapy in older patients (pts) with advanced esophagogastric adenocarcinomas (EGA): the SOCRATE-PRODIGE 55 randomized phase II study
A. Lièvre - Poster CFI PREDICT
Prediction of chemotherapy free interval (CFI) after induction chemotherapy in metastatic colorectal cancer (mCRC) based on a meta-analysis on ARCAD database: the CFI PREDICT project
M. Muller - Poster TOLCO
Factors associated with severe toxicities at 3 months and mortality at 36 months in older patients with colorectal cancer (CRC): a pooled analysis of 3 randomized controlled trials and 3 prospective cohorts.
M. Remond